Robert Lorne Hopfner
CIK 1551966 · last filed 2025-12-22
Robert Lorne Hopfner is a corporate insider who has filed 32 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing shows the insider bought $17.4K of EVMN on Dec 22, 2025. Across all open-market trades the lifetime net is +$3.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $107.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$107.67M
4
32
$3.17M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EVMN | Director | 294,502 | $19.83 | $5.84M | $17.4K | 1 | 2025-12-22 |
| RLYB | Director | 1,694,388 | $15.92 | $26.97M | $7.50M | 7 | 2025-05-15 |
| Inozyme Pharma, Inc. (INZY) Delisted | Director | 2,923,110 | $4.00 | $11.69M | $16.20M | 11 | 2024-06-20 |
| PCVX | Director | 1,577,316 | $47.46 | $74.86M | -$20.55M | 11 | 2021-06-03 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-22 | EVMN | Buy (P) | +1,000 | $17.4K | EDGAR |
| 2025-11-12 | — | Conv (C) | +3,371,001 | $0 | |
| 2025-07-03 | — | U | −4,494,851 | -$17.98M | |
| 2025-05-15 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-17 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2023-08-03 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +833,333 | $4.00M | EDGAR |
| 2023-06-15 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | RLYB | Grant (A) | — | $0 | EDGAR |